• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Whether You Like Illumina or Not, Here Are 2 Trade Ideas

Who do you think probably better understands this business... one of the very best analysts on the entire street or the FTC?
By STEPHEN GUILFOYLE
Apr 06, 2021 | 10:46 AM EDT
Stocks quotes in this article: ILMN

Before we get excited, Illumina (ILMN) does not report for another two and a half weeks. At least now we should not be surprised. We all had our eyes on one ball, in the air, while the juggler was actually doing amazing things with his hands just out of our sight. The story really begins back in September. Big news! Illumina, a firm focused on large scale analysis of genetic variation and biological function, which is huge right now for obvious reasons, to acquire GRAIL, a healthcare company more focused on the early detection of multiple cancer types in a cash and stock deal reportedly worth roughly $8 billion. The deal already had the approval of both boards involved.

Fast forward to just a week ago. The FTC (Federal Trade Commission) filed a complaint to block this deal alleging that the proposed merger would diminish domestic innovation in MECD (Multi-Cancer Early Detection) testing. The Commission in a 4-0 vote authorized its staff to seek a temporary restraining order preventing the firms from moving forward with their plans. The stock sold off 6.6% the day that news broke.

The Voice

Just a day after the FTC took action, so did very highly ranked (5 stars at TipRanks, number 77 of over 7,400 analysts ranked) Max Masucci of Canaccord Genuity, who upgraded the name to a "Buy" from a "Hold", while lifting his price target to $445 from $410. Masucci allowed for COVID-related uncertainty, and cited a brighter post-COVID future for the firm as patients with non-COVID related health issues resume addressing these issues. Masucci also opined on the FTC challenge, referring to the proposed deal as a vertical merger of two companies not in direct competition. Hmm. Who do you think probably better understands this business... one of the very best analysts on the entire street or the FTC? Eggsactly.

Monday Night

Illumina let the street know ahead of earnings that the firm now expects to report Q1 2021 revenue of $1.09 billion, well above the $925 million that the community of sell-side analysts is looking for and good enough for year over year growth of 26%. I see a quarter in 2017 and another one in 2018 where Illumina grew revenue of nearly 26%, but nothing close since. For fiscal 2021 in its entirety, Illumina expects revenue growth to stay right there, in a 25% to 28% range. The growth is across the board, from nearly astounding growth in sequencing instrument sales growth to healthy growth in both sequencing consumables and sequencing itself.

The stock took off overnight, and shortly after the opening bell, I saw the shares up 8.8% for the day so far.

What I see here is what now looks loosely like a double bottom pattern with a pivot of $432. Relative Strength still has plenty of room to run, and the daily MACD looks poised to send a bullish signal. The only thing that overtly sticks me in the back is that gap. The high on Monday was about $388, and the low so far on Tuesday was close to $414.

Now, gaps don't have to fill, but they usually do, and that is one big gap with earnings due on Friday, April 23rd. This is going to be a risky period for the equity. I don't see any way around that.

Trade Ideas (minimal lots)

Idea One: You like the stock...

- Purchase 100 shares of ILMN at or close to the last sale of $417.

- Sell one January 2022 ILMN $450 call for about $48. (Illiquid series, you will need to use some finesse.)

Net Basis: $369.

Note: Profit is capped at 22% through January (9 months)

Idea Two: You don't like the stock...

- Purchase one April 23rd ILMN $415 put for roughly $12 (Illiquid series)

- Sell one April 23rd ILMN $400 put for about $6 (Illiquid series)

Net Debit $6

Note: Trader is risking $600 to try to win back up to $1,500.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Mergers and Acquisitions | Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Analyst Actions

More from Investing

4 Reasons to Be Cautiously Optimistic About the Tech Sector

Eric Jhonsa
May 25, 2022 5:15 PM EDT

Many tech valuations are now back to 2016 or 2017 levels, and quite a few contrarian indicators point to extreme bearishness.

Forget Hunting for a Bottom, Now Traders Just Want the Pain to Stop

James "Rev Shark" DePorre
May 25, 2022 4:36 PM EDT

No one trusts a bounce to last at this point, and they simply are hoping for some relief from the unpleasant action.

I'm Going to Let the Air Out of a Fundamental Rating of Air Products

Bruce Kamich
May 25, 2022 3:30 PM EDT

APD got a "Buy" recommendation, but my analysis doesn't jibe.

As Pioneer Natural Resources Blazes a Trail Higher, We Have New Price Targets

Bruce Kamich
May 25, 2022 2:50 PM EDT

Here's our updated bullish strategy on PXD.

Home Depot's Charts Are Building Out Nicely

Bruce Kamich
May 25, 2022 1:24 PM EDT

Investors can measure out their long positions at these levels.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login